Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS: Daratumumab in relapsed/refractory multiple myeloma
NCT01985126Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Sep 2013; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01985126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01985126.